首页> 美国卫生研究院文献>other >Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100 a Novel Potent and Irreversibly Binding Probe
【2h】

Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100 a Novel Potent and Irreversibly Binding Probe

机译:映射大麻素1受体的变构位点:关键分子决定因素和GAT100一种新型的有力的和不可逆地结合探针的信号传导概况。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

One of the most abundant G-protein coupled receptors (GPCRs) in brain, the cannabinoid 1 receptor (CB1R), is a tractable therapeutic target for treating diverse psychobehavioral and somatic disorders. Adverse on-target effects associated with small-molecule CB1R orthosteric agonists and inverse agonists/antagonists have plagued their translational potential. Allosteric CB1R modulators offer a potentially safer modality through which CB1R signaling may be directed for therapeutic benefit. Rational design of candidate, druglike CB1R allosteric modulators requires greater understanding of the architecture of the CB1R allosteric endodomain(s) and the capacity of CB1R allosteric ligands to tune the receptor’s information output. We have recently reported the synthesis of a focused library of rationally designed, covalent analogues of and PSNCBAM-1, two prototypic CB1R negative allosteric modulators (NAMs). Among the novel, pharmacologically active CB1R NAMs reported, the isothiocyanate GAT100 emerged as the lead by virtue of its exceptional potency in the [35S]GTPγS and β-arrestin signaling assays and its ability to label CB1R as a covalent allosteric probe with significantly reduced inverse agonism in the [35S]GTPγS assay as compared to . We report here a comprehensive functional profiling of GAT100 across an array of important downstream cell-signaling pathways and analysis of its potential orthosteric probe-dependence and signaling bias. The results demonstrate that GAT100 is a NAM of the orthosteric CB1R agonist CP55,940 and the endocannabinoids 2-arachidonoylglycerol and anandamide for β-arrestin1 recruitment, PLCβ3 and ERK1/2 phosphorylation, cAMP accumulation, and CB1R internalization in HEK293A cells overexpressing CB1R and in Neuro2a and STHdhQ7/Q7 cells endogenously expressing CB1R. Distinctively, GAT100 was a more potent and efficacious CB1R NAM than and PSNCBAM-1 in all signaling assays and did not exhibit the inverse agonism associated with and PSNCBAM-1. Computational docking studies implicate C7.38(382) as a key feature of GAT100 ligand-binding motif. These data help inform the engineering of newer-generation, druggable CB1R allosteric modulators and demonstrate the utility of GAT100 as a covalent probe for mapping structure–function correlates characteristic of the druggable CB1R allosteric space.
机译:大麻素1受体(CB1R)是大脑中最丰富的G蛋白偶联受体(GPCR)之一,是治疗各种心理行为和躯体疾病的易处理治疗靶标。与小分子CB1R正构激动剂和反向激动剂/拮抗剂相关的不良靶向作用已困扰其翻译潜力。变构CB1R调节剂提供了一种可能更安全的方式,通过该方式可以指导CB1R信号传导以获得治疗益处。候选药物样CB1R变构调节剂的合理设计需要对CB1R变构内域的结构和CB1R变构配体调节受体信息输出的能力有更多的了解。我们最近报告了一个集中设计的库,该库经过合理设计,与PSNCBAM-1和PSNCBAM-1(两个原型CB1R负变构调节剂(NAM))共价类似。在新颖的,具有药理活性的CB1R NAM中,异硫氰酸酯GAT100凭借其在[ 35 S]GTPγS和β-arrestin信号传导测定中的超强效能以及将CB1R标记为[ 35 S]GTPγS分析中与相比,具有显着降低的反向激动作用的共价变构探针。我们在此报告了一系列重要的下游细胞信号通路中GAT100的全面功能分析,并分析了其潜在的正构探针依赖性和信号偏倚。结果表明,GAT100是正构性CB1R激动剂CP55,940和内源性大麻素2-花生四烯酸甘油酯和Anandamide的NAM,用于β-arrestin1募集,PLCβ3和ERK1 / 2磷酸化,cAMP积累以及在过表达CB1R和HEK293A的HEK293A细胞中的CB1R内在化。内源性表达CB1R的Neuro2a和STHdh Q7 / Q7 细胞。与众不同的是,在所有信号转导分析中,GAT100是比PSNCBAM-1更有效和有效的CB1R NAM,并且没有表现出与PSNCBAM-1相关的反向激动作用。计算对接研究表明C7.38(382)是GAT100配体结合基序的关键特征。这些数据有助于为新一代可药物治疗的CB1R变构调节剂的工程提供信息,并证明了GAT100作为共价探针绘制结构-功能与可药物治疗的CB1R变构空间的特征相关的功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号